Patents Examined by Jeanine Goldberg
  • Method for preventing progression to metabolic syndrome
    Patent number: 10731219
    Abstract: The method for preventing progression to metabolic syndrome includes determining whether a subject possesses at least one allele of the caveolin-1 rs1997623 C to A SNP, and providing an intervention to prevent progression to metabolic syndrome, including modifications of diet and exercise, administration of one or more pharmaceutical compounds, or a combination thereof. The method may be useful to reduce the risk of developing complications associated with MetS, such as heart disease, stroke, or diabetes. The method may include monitoring additional metabolic risk factors. The pharmaceutical compound may be a pharmaceutical capable of inhibiting the expression of caveolin-1.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: August 4, 2020
    Assignee: Dasman Diabetes Institute
    Inventors: Fahd Al Mulla, Rasheeba Nizam, Ashraf Madhoun
  • Markers for prenatal diagnosis and monitoring
    Patent number: 10731217
    Abstract: Methods and kits are provided for diagnosing, monitoring, or predicting preeclaimpsia in a pregnant woman, trisomy 18 and trisomy 21 in a fetus, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more RNA species derived from a set of genetic loci and comparing the amount of the RNA species with a standard control.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: August 4, 2020
    Assignee: The Chinese University of Hong Kong
    Inventors: Yuk-Ming Dennis Lo, Rossa Wai Kwun Chiu, Stephen Siu Chung Chim, Nancy Bo Yin Tsui
  • Marker associated with powdery mildew resistance in plant of genus and use thereof
    Patent number: 10724093
    Abstract: This invention intends to develop many DNA markers for a plant of the genus Fragaria and detect powdery mildew resistance with high precision by using the many DNA markers. The marker associated with powdery mildew resistance in a plant of the genus Fragaria comprises a continuous nucleic acid region sandwiched between the nucleotide sequence as shown in SEQ ID NO: 1 and the nucleotide sequence as shown in SEQ ID NO: 19 in the chromosome of the plant of the genus Fragaria.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: July 28, 2020
    Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHA
    Inventors: Hiroaki Koishihara, Hiroyuki Enoki, Masayoshi Muramatsu, Satoru Nishimura, Susumu Yui, Masanori Honjo
  • Method to predict likelihood of inherited peripheral neuropathy in mammals
    Patent number: 10724098
    Abstract: Methods and kits for diagnosing propensity to exhibit acquired peripheral neuropathy in dogs are described. The methods and kits test dogs for presence of a single-nucleotide polymorphism (SNP) TIGRP2P18586_rs8746233. Presence of the SNP indicates an increased likelihood of the dog exhibiting an acquired peripheral neuropathy. This information can be used to guide preemptive clinical treatment of the animal for peripheral neuropathy and to choose dogs for selective breeding programs.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: July 28, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Peter Muir, Susannah Sample, John Svaren
  • Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
    Patent number: 10718023
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: July 21, 2020
    Assignee: Celera Corporation
    Inventor: Hongjin Huang
  • Method for gender identification in domestic chicken
    Patent number: 10711305
    Abstract: The present invention relates to a method for the detection of the presence or absence of at least one nucleic acid sequence specific for the sex of chicken using polymerase chain reaction in a high-throughput manner, a kit for conducting the method of the present invention and a pair of oligonucleotides.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: July 14, 2020
    Assignee: DIREGG GMBH
    Inventors: Martin Christian Weigel, Karsten Hofmann-Peiker, Michael Kleine
  • Compositions and methods for diagnosing and monitoring hyperthyroidism in a feline
    Patent number: 10704102
    Abstract: The present invention provides a method of diagnosing the existence or risk of hyperthyroidism in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of, e.g., IYD, TG, SLC5A5, NIS, TPO, TSHR, DUOX1, DUOX2 (ThOX), TGFB1, CSTD, DCN and SEPP1 and the expression products thereof, in a biological sample from the feline, wherein elevated expression of the one or more biomarkers in the sample relative to a control value for expression in a sample from a normal feline or feline population, or a baseline value from the feline, indicates the existence or risk of hyperthyroidism; a method of treating a feline so diagnosed; and compositions, reagents and kits for carrying out the specified methods.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: July 7, 2020
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Samer Waleed Khedheyer Al-Murrani, Xiangming Gao
  • Compositions and methods for diagnosing and monitoring hyperthyroidism in a feline
    Patent number: 10704103
    Abstract: The present invention provides a method of diagnosing the existence or risk of hyperthyroidism in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of, e.g., IYD, TG, SLC5A5, NIS, TPO, TSHR, DUOX1, DUOX2 (ThOX), TGFB1, CSTD, DCN and SEPP1 and the expression products thereof, in a biological sample from the feline, wherein elevated expression of the one or more biomarkers in the sample relative to a control value for expression in a sample from a normal feline or feline population, or a baseline value from the feline, indicates the existence or risk of hyperthyroidism; a method of treating a feline so diagnosed; and compositions, reagents and kits for carrying out the specified methods.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: July 7, 2020
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Samer Waleed Khedheyer Al-Murrani, Xiangming Gao
  • Methods of detecting breast cancer brain metastasis with genomic and epigenomic biomarkers
    Patent number: 10697021
    Abstract: The present invention provides a method of diagnosing a breast cancer central nervous system (CNS) metastasis in a subject, comprising determining the expression level of at least one biomarker in a subject-derived brain or breast tissue comparing the subject-derived expression level with a normal control level obtained from normal brain or breast cells; and correlating an increase or decrease of the subject-derived expression level as compared to the normal control level to a diagnosis of a breast cancer CNS metastasis. The present invention also provides a method for the treatment of a breast cancer CNS metastasis in a subject comprising administering to the subject an inhibitor of an overexpressed gene associated with CNS metastasis.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: June 30, 2020
    Assignee: The Translational Genomics Research Institute
    Inventor: Bodour Salhia
  • Test kits and methods for their use to detect genetic markers for urothelial carcinoma of the bladder and treatment thereof
    Patent number: 10689711
    Abstract: This invention relates to methods for detecting the presence of genetic markers for transitional cell carcinoma of the bladder. Specifically, this invention relates to detection of expression of overexpressed and underexpressed genetic markers and calculation of ratios of expression of these markers. In additional aspects, the invention relates to polymerase chain reaction (PCR) based kits for carrying out these methods.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: June 23, 2020
    Assignee: PACIFIC EDGE LIMITED
    Inventor: Parry John Guilford
  • Detecting neoplasm
    Patent number: 10683555
    Abstract: Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as pancreatic and colorectal cancer.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: June 16, 2020
    Assignees: Mayo Foundation for Medical Education and Research, Exact Sciences Development Company, LLC
    Inventors: David A. Ahlquist, John B. Kisiel, William R. Taylor, Tracy C. Yab, Douglas W. Mahoney, Graham P. Lidgard, Hatim T. Allawi
  • PIK3CA fusions
    Patent number: 10669590
    Abstract: The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) gene fusions, and fragments of those gene fusions. The invention further provides methods of diagnosing and treating diseases or disorders associated with PIK3CA fusions, such as conditions mediated by PIK3CA aberrant expression or activity, or overexpression of PIK3CA.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: June 2, 2020
    Assignee: Blueprint Medicines Corporation
    Inventors: Ethan G. Cerami, Christoph Lengauer, Nicolas Stransky
  • Bioagent detection oligonucleotides
    Patent number: 10662485
    Abstract: The present invention compositions, methods and systems to identify, detect, and/or quantify bacterial DNA in the presence of contaminating non-bacterial DNA. In particular, the present invention provides oligonucleotides configured to detect a relatively small amount of bacterial DNA in the presence of an overwhelmingly large amount of contaminating human DNA.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: May 26, 2020
    Assignee: IBIS BIOSCIENCES, INC.
    Inventors: David J. Ecker, Steven A. Hofstadler, Rangarajan Sampath, Lawrence B. Blyn, Thomas A. Hall, Mark W. Eshoo
  • Personalized pain management and anesthesia: preemptive risk identification and therapeutic decision support
    Patent number: 10662476
    Abstract: Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: May 26, 2020
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Senthilkumar Sadhasivam, Vidya Chidambaran, John McAuliffe, Kejian Zhang, Jaroslaw Meller, Cynthia A. Prows, Tsuyoshi Fukuda
  • Genetic marker for early breast cancer prognosis prediction and diagnosis, and use thereof
    Patent number: 10655187
    Abstract: The present invention relates to a gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof, and more specifically relates to a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker of the present invention allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: May 19, 2020
    Assignee: GENCURIX INC.
    Inventors: Young Kee Shin, Young-Deug Kim, En Sel Oh, Jun Young Choi, Sang Rea Cho
  • Methods and compositions for detecting Zika virus
    Patent number: 10626473
    Abstract: Provided herein is a highly sensitive and robust method for Zika detection in semen, as well as related compositions. The method can include: (a) extracting nucleic acids from a human semen sample; (b) detecting Zika virus nonstructural protein 5 (NS5) mRNA using real-time reverse-transcription polymerase chain reaction (rRT-PCR); and (c) simultaneously, in the rRT-PCR, detecting human beta-actin mRNA as positive control.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: April 21, 2020
    Assignee: Genetics & IVG Institute, Inc.
    Inventors: Brian D. Mariani, Harvey J. Stern
  • Materials and methods for detecting source body fluids
    Patent number: 10619218
    Abstract: The invention pertains to analyzing the levels of DNA methylation at specific genetic loci to detect specific body fluids, for example, vaginal secretions or vaginal epithelial cells, semen or sperms, saliva or buccal epithelial cells, or blood or blood cells. Particularly, the levels of methylation of DNA at the genetic loci corresponding to SEQ ID NOs: 1, 6, 11, and 16 are used to detect vaginal secretions or vaginal epithelial cells, semen or sperms, saliva or buccal epithelial cells, and blood or blood cells, respectively. The level of methylation at the specific loci can be determined by high-resolution melt analysis (HRM) or sequencing of the amplicons produced using specific primers designed to amplify the specific loci. Kits containing the primers and reagents for carrying out the methods disclosed herein are also provided.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: April 14, 2020
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Bruce McCord, Joana Antunes
  • Method of evaluating the response of ataxia telangiectasia patients to glucocorticoids treatment
    Patent number: 10619208
    Abstract: The present invention relates to a novel procedure for evaluating the response of patients affected by Ataxia Talangiectasia (A-T) to glucocorticoids treatment. In particular, the procedure provides a step of qualitative and/or quantitative identification in the blood of said patients of the expression of a mRNA variant of the ATM (Ataxia-Talangiectasia-Mutated) gene produced by non-canonical splicing induced by glucocorticoid (GC). In fact, it was demonstrated that mRNA variant expression is present in the blood of patients who responded positively to treatment with GC.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: April 14, 2020
    Assignee: EryDel S.p.A.
    Inventors: Mauro Magnani, Sara Biagiotti, Michele Menotta
  • Compositions and methods for detection of
    Patent number: 10612101
    Abstract: Methods for the rapid detection of the presence or absence of Mycoplasma genitalium (MG) in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers, probes targeting the target MG gene, along with kits are provided that are designed for the detection of MG.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: April 7, 2020
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Jody Harris, Kalyani Mangipudi
  • Marker for prenatal diagnosis and monitoring
    Patent number: 10604808
    Abstract: The present invention relates to new methods for diagnosing a pregnancy-associated disorder by analyzing fetal DNA present in the mother's blood. More specifically, this invention relies on the discovery that the maspin gene is differentially methylated in fetal DNA and in maternal DNA and provides these new diagnostic methods, which distinguish fetal DNA from maternal DNA and detect prenatal disorders based on abnormalities in fetal DNA level and methylation status.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: March 31, 2020
    Assignee: The Chinese University of Hong Kong
    Inventors: Yuk Ming Dennis Lo, Rossa Wai Kwun Chiu, Stephen Siu Chung Chim, Yu-Kwan Tong, Chunming Ding